Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus

Francesco Trotta, Gianluigi Bajocchi, R. La Corte, S. Moratelli, Lingyun Sun
In: Rheumatology · 1999 · vol. 38(10) , pp. 1007–1009 · doi:10.1093/rheumatology/38.10.1007 · PMID:10534554 · W2112061856
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

Acquired deficiency of clotting factor VIII (FVIII) is a rare bleeding diathesis seldom encountered in systemic lupus erythematosus (SLE). Reduction of FVIII activity by autoantibodies can cause potentially life-threatening situations. Herein, an SLE patient with a positive lupus anticoagulant (LAC) test who abruptly developed metrorrhagia 4 yr after diagnosis is reported. Coagulation tests revealed FVIII activity reduced to 3% and a prolonged aPTT. FVIII inhibitor(s) were found to be as high as 3.0 Bethesda Units. Plasmapheresis, immunoglobulins, prednisolone and FVIII plasma concentrates induced the cessation of metrorrhagia, but the clotting tests were barely improved. One month later, extensive ecchymosis appeared and worsened, despite re-administration of the previous therapy. Pulse cyclophosphamide followed by oral administration was then started with normalization of coagulation parameters and long-lasting disease remission.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (15)

Source provenance

openalex
last seen: 2026-05-11T06:12:37.668444+00:00
License: CC0 · commercial use OK